Compare Keysight Technologies Inc (KEYS) vs 10X Genomics Inc (TXG) Price & Performance

Keysight Technologies (KEYS) trades at $382.61, up 0.29% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with accelerating earnings, beating estimates for three consecutive quarters, and impressive profitability metrics including 19.14% net income margin and 20.59% ROE. Recent news highlights AI infrastructure demand and 6G development opportunities, positioning the company for continued growth.

KEYS presents a compelling investment case with strong analyst consensus (81% buy ratings) and a $416.63 price target offering 8.9% upside. However, elevated valuation ratios (P/E 50.7, P/S 9.85) and supply chain constraints present near-term risks. The company's leadership in AI testing and 6G technology provides long-term growth catalysts despite current premium pricing.

10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.

The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.